Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rabeprazole sodium Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

NCT00747526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Rabeprazole Protection of Aspirin Induced Gastric Damage.

NCT00220857
View directory record Official record
Conditions
Normal Subjects
Interventions
Rabeprazole
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT01918176
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 4 Interventional

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7890597, Placebo, Rabeprazole, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00911534
View directory record Official record
Conditions
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Interventions
rabeprazole sodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
98
States / cities
Athens, Alabama • Huntsville, Alabama • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

NCT00199953
View directory record Official record
Conditions
Postnasal Drainage
Interventions
Rabeprazole 20 mg twice a day for 90-day period treatment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

NCT03094416
View directory record Official record
Conditions
Hypothyroidism;Postablative
Interventions
levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Ventura, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928
View directory record Official record
Conditions
Healthy Adults, Healthy
Interventions
PF-08049820, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

NCT00287391
View directory record Official record
Conditions
Insomnia, GERD
Interventions
Rabeprazole
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 19, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

NCT00236197
View directory record Official record
Conditions
Heartburn
Interventions
rabeprazole sodium, placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
19 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 19, 2026, 5:05 PM EDT